Integra LifeSciences Holdings Dirección

Dirección controles de criterios 3/4

El CEO de Integra LifeSciences Holdings es Jan De Witte , nombrado en Dec 2021, tiene una permanencia de 2.92 años. compensación anual total es $6.39M, compuesta por 13.7% salario y 86.3% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.031% de las acciones de la empresa, por valor de €527.99K. La antigüedad media del equipo directivo y de la junta directiva es de 3.6 años y 11.5 años, respectivamente.

Información clave

Jan De Witte

Chief Executive Officer (CEO)

US$6.4m

Compensación total

Porcentaje del salario del CEO	13.7%
Permanencia del CEO	2.9yrs
Participación del CEO	0.03%
Permanencia media de la dirección	3.6yrs
Promedio de permanencia en la Junta Directiva	11.5yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Jan De Witte en comparación con los beneficios de Integra LifeSciences Holdings?
Fecha	Compensación total	Salario	Ingresos de la empresa
Sep 30 2024	n/a	n/a	-US$7m
Jun 30 2024	n/a	n/a	US$24m
Mar 31 2024	n/a	n/a	US$40m
Dec 31 2023	US$6m	US$875k	US$68m
Sep 30 2023	n/a	n/a	US$101m
Jun 30 2023	n/a	n/a	US$131m
Mar 31 2023	n/a	n/a	US$172m
Dec 31 2022	US$9m	US$850k	US$181m
Sep 30 2022	n/a	n/a	US$173m
Jun 30 2022	n/a	n/a	US$166m
Mar 31 2022	n/a	n/a	US$157m
Dec 31 2021	US$899k	US$59k	US$169m

Compensación vs. Mercado: La compensación total de Jan($USD6.39M) está por encima de la media de empresas de tamaño similar en el mercado German ($USD1.63M).

Compensación vs. Ingresos: La compensación de Jan ha sido consistente con los resultados de la empresa en el último año.

CEO

Jan De Witte (60 yo)

2.9yrs

Permanencia

US$6,388,756

Compensación

Mr. Jan De Witte has been President, Chief Executive Officer & Director of Integra LifeSciences Holdings Corporation since December 1, 2021. He had been the Chief Executive Officer at Barco NV since Septem...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Stuart Essig	Executive Chairman	26.9yrs	US$422.52k	2.27% € 38.7m
Jan De Witte	President	2.9yrs	US$6.39m	0.031% € 528.0k
Lea Knight	Executive VP & CFO	1.4yrs	US$1.67m	0.054% € 926.3k
Jeffrey Mosebrook	Senior VP of Finance & Principal Accounting Officer	7.1yrs	US$1.25m	0.047% € 797.1k
Eric Schwartz	Executive VP	6yrs	US$1.62m	0.082% € 1.4m
Robert Davis	Executive VP & President of Tissue Technologies	11.9yrs	US$1.42m	0.084% € 1.4m
Michael McBreen	Executive VP & President of Codman Specialty Surgical	4.5yrs	US$2.83m	0.075% € 1.3m
Stephen Leonard	Corporate VP of Global Operations & Supply Chain	4.3yrs	sin datos	sin datos
Laurene Isip	Vice President of Global Corporate Communications & Public Relations	no data	sin datos	sin datos
Ruth Fleming	Vice President of Global Marketing	no data	sin datos	sin datos
Chantal Veillon-Berteloot	Executive VP & Chief Human Resources Officer	1.8yrs	sin datos	0.032% € 538.4k
Mark Jesser	Corporate VP & Chief Digital Officer	2.8yrs	sin datos	sin datos

3.6yrs

Permanencia media

57yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de IL3 se considera experimentado (3.6 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Stuart Essig	Executive Chairman	26.9yrs	US$422.52k	2.27% € 38.7m
Jan De Witte	President	2.9yrs	US$6.39m	0.031% € 528.0k
Raymond Murphy	Independent Director	15.6yrs	US$297.54k	0.11% € 1.8m
Christian Schade	Independent Director	18.8yrs	US$293.28k	0.082% € 1.4m
Barbara Hill	Independent Presiding Director	11.5yrs	US$342.54k	0.18% € 3.0m
Keith N. Bradley	Independent Director	32.8yrs	US$306.31k	0.091% € 1.5m
Jeffrey Graves	Independent Director	less than a year	US$90.68k	0.016% € 275.9k
Shaundra Clay	Independent Director	3.6yrs	US$260.04k	0.028% € 484.2k
Renee Lo	Independent Director	2.3yrs	US$297.54k	0.021% € 356.7k

11.5yrs

Permanencia media

63yo

Promedio de edad

Junta con experiencia: Los miembros de la junta directiva de IL3 son experimentados ( 11.5 años antigüedad media).

Integra LifeSciences Holdings Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Independent Presiding Director recently bought €917k worth of stock

Integra LifeSciences Holdings Corporation, Annual General Meeting, May 09, 2024

Integra LifeSciences Holdings Corporation Announces Board Changes

Integra Lifesciences Holdings Corporation Appoints Lea Daniels Knight as Executive Vice President, Effective June 28, 2023

President recently bought €279k worth of stock

Insider recently sold €95k worth of stock

Recent updates

Integra Lifesciences Holdings Corporation Provides Earnings Guidance for the Fourth Quarter and Updates Earnings Guidance for the Full Year of 2024

Third quarter 2024 earnings released: US$0.14 loss per share (vs US$0.24 profit in 3Q 2023)

Investor sentiment deteriorates as stock falls 21%

Second quarter 2024 earnings released: US$0.16 loss per share (vs US$0.052 profit in 2Q 2023)

Integra LifeSciences Holdings Corporation Provides Earnings Guidance for the Third Quarter and Updates Earnings Guidance for the Full Year of 2024

Integra LifeSciences Holdings Corporation to Report Q2, 2024 Results on Jul 29, 2024

Integra LifeSciences Holdings Corporation(NasdaqGS:IART) dropped from Russell 1000 Dynamic Index

Independent Presiding Director recently bought €917k worth of stock

Integra LifeSciences Holdings Corporation Provides Revenue Guidance for the Second Quarter and Full Year 2024

New minor risk - Share price stability

First quarter 2024 earnings released: US$0.042 loss per share (vs US$0.30 profit in 1Q 2023)

Integra LifeSciences Holdings Corporation (NasdaqGS:IART) acquired 100% stake in Acclarent, Inc. from Ethicon US, LLC for $280 million.

Integra LifeSciences Holdings Corporation to Report Q1, 2024 Results on Apr 25, 2024

Integra LifeSciences Holdings Corporation, Annual General Meeting, May 09, 2024

Integra Lifesciences Launches Micromatrix Flex to Provide Convenient Access to Hard-To-Reach Areas in Complex Cases

Investor sentiment deteriorates as stock falls 19%

Integra LifeSciences Holdings Corporation Announces Board Changes

Integra Lifesciences Holdings Corporation Provides Earnings Guidance for the First Quarter and for the Full Year 2024

Full year 2023 earnings released: EPS: US$0.84 (vs US$2.18 in FY 2022)

Integra LifeSciences Holdings Corporation to Report Q4, 2023 Results on Feb 28, 2024

Integra LifeSciences Holdings Corporation (NasdaqGS:IART) entered into a definitive agreement to acquire 100% stake in Acclarent, Inc. from Ethicon US, LLC for $280 million.

Integra LifeSciences Holdings Corporation (NasdaqGS:IART) entered into a definitive agreement to acquire 100% stake in Acclarent, Inc. from Ethicon US, LLC for $280 million.

Third quarter 2023 earnings released: EPS: US$0.24 (vs US$0.60 in 3Q 2022)

Levi & Korsinsky Notifies Integra Lifesciences Holdings Corporation Investors of a Class Action Lawsuit and Upcoming Deadline

Integra LifeSciences Holdings Corporation to Report Q3, 2023 Results on Oct 25, 2023

Bernstein Litowitz Berger & Grossmann LLP Announces the Filing of Securities Class Action Lawsuit Against Integra Lifesciences Holdings Corporation

Bernstein Litowitz Berger & Grossmann LLP Announces the Filing of Securities Class Action Lawsuit Against Integra Lifesciences Holdings Corporation

New minor risk - Earnings quality

Integra LifeSciences Holdings Corporation (NasdaqGS:IART) announces an Equity Buyback for $225 million worth of its shares.

Second quarter 2023 earnings released: EPS: US$0.052 (vs US$0.54 in 2Q 2022)

Integra LifeSciences Holdings Corporation to Report Q2, 2023 Results on Jul 27, 2023

Integra LifeSciences Holding Corporation Announces Complete Enrollment in DuraSorb Monofilament Mesh U.S. IDE Study

Integra Lifesciences Holdings Corporation Appoints Lea Daniels Knight as Executive Vice President, Effective June 28, 2023

President recently bought €279k worth of stock

Now 35% undervalued after recent price drop

Now 20% undervalued after recent price drop

First quarter 2023 earnings released: EPS: US$0.29 (vs US$0.39 in 1Q 2022)

Insider recently sold €95k worth of stock

Insider recently sold €203k worth of stock

Full year 2022 earnings released: EPS: US$2.16 (vs US$2.00 in FY 2021)

Now 20% undervalued

Integra LifeSciences Holdings Corporation Announces Executive Changes

Now 21% undervalued

Integra LifeSciences Holdings Corporation Provides Revenue Guidance for Fourth Quarter 2022 and Full-Year 2022

Integra LifeSciences Holdings Corporation (NasdaqGS:IART) completed the acquisition of Surgical Innovation Associates, Inc.

Integra LifeSciences Holdings Corporation (NasdaqGS:IART) entered into a definitive agreement to acquire Surgical Innovation Associates, Inc. for $140 million.

Third quarter 2022 earnings released: EPS: US$0.60 (vs US$0.51 in 3Q 2021)

Integra LifeSciences Holdings Corporation Provides Earnings Guidance for the Fourth Quarter and Full Year

Integra LifeSciences Holdings Corporation to Report Q3, 2022 Results on Oct 26, 2022

Integra LifeSciences Holdings Corporation Appoints Harvinder Singh as Executive Vice President and President of Integra’s International Business

Integra LifeSciences Holdings Corporation Announces Resignation of Glenn Coleman as Chief Operating Officer, Effective October 3, 2022

Integra LifeSciences Announces the Passing of Dr. Richard Caruso, Founder and Former Chairman and CEO

Independent Director recently sold €439k worth of stock

An unknown buyer entered into a definitive agreement to acquire Non-core Traditional Wound Care Business of Integra LifeSciences Holdings Corporation (NasdaqGS:IART) for $28.8 million.

Second quarter 2022 earnings released: EPS: US$0.54 (vs US$0.41 in 2Q 2021)

Integra LifeSciences Holdings Corporation Revises Financial Guidance for the Third Quarter and Full Year 2022

Integra LifeSciences Holdings Corporation Appoints Renee Lo to its Board of Directors

Integra LifeSciences Holdings Corporation to Report Q2, 2022 Results on Jul 27, 2022

First quarter 2022 earnings released: EPS: US$0.39 (vs US$0.54 in 1Q 2021)

Integra LifeSciences Holdings Corporation, Annual General Meeting, May 13, 2022

Integra LifeSciences Holdings Corporation to Report Q1, 2022 Results on Apr 27, 2022

Insider recently sold €75k worth of stock

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Integra LifeSciences Holdings Corporation Provides Earnings Guidance for the First Quarter and Full Year 2022

Integra LifeSciences Holdings Corporation Provides Revenue Guidance for the Fourth Quarter and Full Year 2021

Insider recently sold €214k worth of stock

Third quarter 2021 earnings released: EPS US$0.51 (vs US$0.38 in 3Q 2020)

Insider recently sold €242k worth of stock

Second quarter 2021 earnings released: EPS US$0.41 (vs US$0.004 loss in 2Q 2020)